PF-06747711

Cat. No.:	HY-112706
CAS No.:	1892576-58-7
Molecular Formula:	$C_{26}H_{26}F_3N_5O_2$
Molecular Weight:	497.51
Target:	ROR
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 41.67 mg/mL (83.76 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0100 mL	10.0500 mL	20.1001 mL
	5 mM	0.4020 mL	2.0100 mL	4.0200 mL
	10 mM	0.2010 mL	1.0050 mL	2.0100 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.18 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (4.18 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.18 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) inverse agonist, with an IC_{50} of 4.1 nM. Anti-skin inflammatory activity[1].

IC_{50} & Target

IC50: 4.1 nM (RORC2)[1]

In Vitro

PF-06747711 (Compound 66) reduces IL-17 production by human Th17 cells with an IC_{50} of 9.5 nM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PF-06747711 (10, 30, and 100 mg/kg, p.o., daily over 5 days) inhibits ear swelling in a dose-dependent manner in mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8–10 week old female Balb/c mice[1]
Dosage:	10, 30, and 100 mg/kg
Administration:	P.O. daily over 5 days
Result:	Inhibited ear swelling, and caused a maximum inhibition of 46% at 100 mg/kg.

REFERENCES

[1]. Schnute ME, et al. Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. J Med Chem. 2018 Sep 9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA